Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Incyte.
December 8, 2017
Lunch and registration: 12:30 PM – 1:30 PM
Georgia World Congress Center
Meeting Room: A402-A403
285 Andrew Young International Blvd NW
Atlanta, GA 30313
Graft-versus-host disease (GvHD) is a leading cause of morbidity and mortality among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). An immune-mediated disorder, GvHD can manifest as an acute or chronic syndrome, each of which presents unique challenges for clinicians who encounter them. The clinical ramifications of these disorders and their rising incidence worldwide make it critical for hematologists who manage patients with hematological malignancies to maintain knowledge and competence concerning GvHD. During this activity, renowned experts will review and discuss aspects of GvHD important to cancer care providers, including its pathophysiology, assessment of patient risk for GvHD, diagnostic challenges, management recommendations, prevention and mitigation of adverse events, patient counseling considerations, and emerging therapeutic options. Additionally, the program will include a preview of GvHD data to be presented at the Annual Meeting.To help put information into its proper context, this program includes several interactive case-based faculty panel discussions and question-and-answer sessions.
This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.
After successful completion of this educational activity, participants should be better able to:
John F. DiPersio, MD, PhD
Virginia E. and Samuel J. Golman Professor
Chief, Division of Oncology
Deputy Director, Siteman Cancer Center
Washington University School of Medicine
St Louis, MO
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018